| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 69 | 91 | 45 | 61 |
| Cost of Material Consumed | 41 | 41 | 22 | 37 |
| Change in Inventory | -5 | 3 | 2 | 2 |
| Gross Margins | 40.58 | 54.95 | 51.11 | 39.34 |
| Employee Benefit Expenses | 4 | 6 | 5 | 4 |
| Other Expenses | 21 | 31 | 13 | 14 |
| EBITDA | 8 | 10 | 3 | 4 |
| OPM | 11.59 | 10.99 | 6.67 | 6.56 |
| Other Income | 0.5 | 0.1 | 0.8 | 1.35 |
| Finance Cost | 0 | 0 | 0.4 | 0.42 |
| D&A | 0 | 0 | 0.3 | 0.39 |
| EBIT | 8 | 10 | 2.7 | 3.61 |
| EBIT Margins | 11.59 | 10.99 | 6 | 5.92 |
| PBT | 7 | 10 | 3 | 3.31 |
| PBT Margins | 10.14 | 10.99 | 6.67 | 5.43 |
| Tax | 2 | 2 | 0.7 | 0.87 |
| PAT | 5 | 8 | 2.3 | 2.44 |
| NPM | 7.25 | 8.79 | 5.11 | 4 |
| EPS | 166.67 | 266.67 | 71.88 | 76.25 |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | 11.59 | 10.99 | 6.67 | 6.56 |
| Net Profit Margin | 7.25 | 8.79 | 5.11 | 4 |
| Earning Per Share (Diluted) | 166.67 | 266.67 | 71.88 | 76.25 |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | 1.6 | 2 | 2.6 | 2 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 1 | 2.4 | 3.5 |
| Trade Receivables | 6 | 7 | 7 | 8 |
| Inventory | 14 | 12 | 9 | 7 |
| Other Assets | 11.4 | 19 | 19 | 20.5 |
| Total Assets | 33 | 41 | 40 | 41 |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 0.3 | 0.3 | 0.32 | 0.32 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 22 | 29 | 32 | 34 |
| Borrowings | 4 | 4 | 4.5 | 4 |
| Trade Payables | 6 | 6 | 2.5 | 2 |
| Other Liabilities | 0.7 | 1.7 | 0.68 | 0.68 |
| Total Liabilities | 33 | 41 | 40 | 41 |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | 7 | 10 | 3 | 3.31 |
| OPBWC | 8 | 10 | 3.25 | 2.86 |
| Change in Receivables | -0.7 | -0.6 | -0.34 | -0.82 |
| Change in Inventories | -5.4 | 2 | 2.6 | 1.82 |
| Change in Payables | 1 | 0.7 | -3.91 | -0.62 |
| Other Changes | 0.1 | -1 | 2 | -0.3 |
| Working Capital Change | -5 | 1.1 | 0.35 | 0.08 |
| Cash Generated From Operations | 3 | 11.1 | 3.6 | 2.94 |
| Tax | 0 | 0 | 0 | 0 |
| Cash Flow From Operations | 3 | 11.1 | 3.6 | 2.94 |
| Purchase of PPE | -0.3 | -0.9 | -0.68 | -0.08 |
| Sale of PPE | 0 | 0 | 0 | 0 |
| Cash Flow From Investment | 0 | -1.7 | -0.87 | -0.06 |
| Borrowing | 0.9 | -0.2 | 0 | -0.45 |
| Dividend | 0 | 0 | 0 | 0 |
| Equity | 0 | 0 | 0.41 | 0 |
| Others From Financing | -2.5 | -3.4 | -1.55 | -1.39 |
| Cash Flow from Financing | -1.6 | -3.6 | -1.14 | -1.84 |
| Net Cash Generated | 1.4 | 5.8 | 1.59 | 1.04 |
| Cash at the Start | 8.8 | 10 | 16 | 17.6 |
| Cash at the End | 10.2 | 15.8 | 17.59 | 18.64 |
Hicks Thermometers India Limited is one of India’s most trusted and long-standing manufacturers of precision thermometers and medical diagnostic devices. Established over five decades ago, the company has earned a strong reputation for delivering high-quality, reliable, and clinically accurate products used widely in hospitals, laboratories, clinics, and households. Hicks manufactures a diverse portfolio that includes digital thermometers, clinical glass thermometers, infrared thermometers, blood pressure monitors, nebulizers, and other healthcare instruments. Its commitment to quality and adherence to strict manufacturing standards have helped the company maintain a loyal customer base and strong brand recognition in the Indian medical instruments market.
Over the years, Hicks Thermometers has continuously upgraded its production processes, technology, and quality control systems to match global healthcare standards. The company’s modern manufacturing facilities are equipped to produce both traditional and digital diagnostic devices, ensuring a balanced product mix to serve evolving market needs. With the rising demand for home healthcare and preventive health monitoring, Hicks has expanded its distribution network across India and international markets. Its focus on innovation, product accuracy, affordability, and user-friendly designs has enabled it to compete effectively with both domestic and international brands. Hicks’ consistent emphasis on product certification, safety compliance, and robust packaging further strengthens its market presence.
Hicks Thermometers India Limited’s unlisted shares attract investor interest due to the company’s established brand value and the growing healthcare diagnostics industry in India. As consumer awareness around health monitoring increases and demand for reliable medical devices rises, the company stands to benefit from long-term industry tailwinds. While unlisted shares come with inherent challenges such as limited liquidity and restricted public information, Hicks’ steady financial performance, expanding product range, and focus on quality-driven growth contribute to its investment appeal. For investors seeking early exposure to a stable, healthcare-focused manufacturing company, Hicks Thermometers presents a compelling long-term opportunity backed by strong fundamentals and a proven legacy in the medical devices sector.
Q:1 How do I confirm the booking of Hicks Thermometers India Limited Unlisted Shares?Answer: You can confirm the booking of Hicks Thermometers India Limited Unlisted Shares by contacting us and agreeing on a trading price for the shares.
Q:2 What documents do I need to provide to buy Hicks Thermometers India Limited Unlisted Shares?Answer: You need to provide your client master report, PAN Card, and a Cancelled Cheque.If you are not transferring funds from the bank account mentioned in the CMR Copy, these KYC documents are required as per SEBI regulations.
Q:3 How will I receive the bank details for the payment?
Answer: Once you confirm your booking, we will provide you with the necessary bank details for transferring funds.
Q:4 What payment methods are accepted for buying Hicks Thermometers India Limited Unlisted Shares?Answer: Payment must be made via RTGS, NEFT, IMPS, or cheque transfer.Cash deposits are not accepted.
Q:5 Can I pay for the shares from any bank account?
Answer: No, payment must be made from the same bank account where the shares are to be credited.
Q:6 Is it mandatory to use the same bank account for payment and shares credit?Answer: Yes, it is mandatory to use the same bank account for both the payment and the credit of shares as per SEBI regulations.
Q:7 What happens if I don’t have a client master report?
Answer: If you do not have a client master report, you should ask your broker to provide one, as it is necessary for the transaction.
Q:8 Are there any restrictions on the payment methods for unlisted shares?Answer: Yes, payments must be made through RTGS, NEFT, IMPS, or cheque transfer only; cash deposits will not be accepted.